[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623593":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":49,"collaborators":25,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":76,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group I","EXPERIMENTAL","consists of 30 PsA patients who will receive Adalimumab with methotrexate therapy for 3 months.",[13],"Drug: Adalimumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Group II","consists of 30 PsA patients who will receive Apremilast with methotrexate therapy for 3 months.",[18],"Drug: Apremilast",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Adalimumab","PsA patients who will receive Adalimumab with methotrexate therapy for 3 months",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Apremilast","PsA patients who will receive Apremilast with methotrexate therapy for 3 months",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"MennaAllah Elmalla, Assistant lecturer","CONTACT","+20 10 94422540","mennaallah.mohamed@med.tanta.edu.eg",[37],{"facility":5,"status":25,"city":38,"state":25,"zip":25,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Tanta","Egypt","EG",{"type":42,"coordinates":43},"Point",[44,45],31.00192,30.78847,{"lat":45,"lon":44},[48],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","MenaaAllah Mohamed Elmalla","Assistant Lecturer of Rheumatology, Rehabilitation & Physical Medicine","100623593","apremilast-and-adalimumab-in-psoriatic-arthritis-patients-100623593",false,"NCT07398651","Apremilast and Adalimumab in Psoriatic Arthritis Patients","Comparative Study Between Apremilast and Adalimumab in Psoriatic Arthritis Patients","Inclusion Criteria:\n\n* This study will include 60 adult Psoriatic arthritis patients \\>18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months.\n\n  * Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains\n\nExclusion Criteria:\n\n* Patients who received previous biologic agents or Janus kinase inhibitors.\n* Patients with axial and ocular involvement.\n* Current or recent serious infection including tuberculosis or hepatitis B\u002FC .\n* Current or past history of malignancy (within five year).\n* Pregnant or breastfeeding women or women planning pregnancy during the study period .\n* Severe uncontrolled comorbidities such as heart failure, severe liver disease, or chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) .","ALL","18 Years","70 Years",{"count":64,"type":65},60,"ESTIMATED","INTERVENTIONAL",[68],"NA","The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate",[71,72,73],"Psoriatic Arthritis","Ultrasound Assessment","TNF",[75,27,22],"Psoriatic Arthritis Patients:","NOT_YET_RECRUITING","2026-02-09",{"date":79,"type":80},"2026-02-10","ACTUAL",{"date":82,"type":65},"2026-12-30",{"date":82,"type":65},{"name":5,"class":6},1]